AstraZeneca的Imfinzi,加上化疗,提高了早期胃癌的存活率,研究显示。 AstraZeneca's Imfinzi, combined with chemo, improves survival in early-stage gastric cancer, study shows.

AstraZeneca的药物Imfinzi与标准的化疗相结合,表明根据MATTERHORN第三阶段试验,早期胃癌患者的无事件存活率有所改善。 AstraZeneca's drug Imfinzi, when combined with standard chemotherapy, has shown improved event-free survival in early-stage gastric cancer patients, according to the MATTERHORN Phase III trial. 该药物还显示出改善总体生存的强劲趋势。 The drug also showed a strong trend for better overall survival. 胃癌是造成全球癌症死亡的第五个主要原因,每年有近100万例诊断。 Gastric cancer is the fifth leading cause of cancer death globally, with nearly one million annual diagnoses. 治疗的安全情况与已知风险一致,结果将在一次医疗会议上与监管者分享。 The treatment's safety profile aligns with known risks, and the results will be shared at a medical conference and with regulators.